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Abstract
Memantine, a partial antagonist of N-methyl-D-aspartate receptor (NMDAR), approved for 
moderate to severe Alzheimer’s disease (AD) treatment within the US and Europe under brand 
name Namenda (Forest), Axura and Akatinol (Merz), and Ebixa and Abixa (Lundbeck), may have 
potential in alleviating additional neurological conditions, such as vascular dementia (VD) and 
Parkinson’s disease (PD). In various animal models, memantine has been reported to be a 
neuroprotective agent that positively impacts both neurodegenerative and vascular processes. 
While excessive levels of glutamate result in neurotoxicity, in part through the over-activation of 
NMDARs, memantine—as a partial NMDAR antagonist, blocks the NMDA glutamate receptors 
to normalize the glutamatergic system and ameliorate cognitive and memory deficits. The key to 
memantine’s therapeutic action lies in its uncompetitive binding to the NMDAR through which 
low affinity and rapid off-rate kinetics of memantine at the level of the NMDAR-channel preserves 
the physiological function of the receptor, underpinning memantine’s tolerability and low adverse 
event profile. As the biochemical pathways evoked by NMDAR antagonism also play a role in PD 
and since no other drug is sufficiently effective to substitute for the first-line treatment of L-dopa 
despite its side effects, memantine may be useful in PD treatment with possibly fewer side effects. 
In spite of the relative modest nature of its adverse effects, memantine has been shown to provide 
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only a moderate decrease in clinical deterioration in AD and VD, and hence efforts are being 
undertaken in the design of new and more potent memantine-based drugs to hopefully provide 
greater efficacy.
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INTRODUCTION
Alzheimer’s disease (AD), a neurodegenerative disorder characterized by irreversible, 
progressive loss of memory followed by complete dementia, is marked by cognitive decline 
accompanied by impaired performance of daily activities, behavior, speech and visual-
spatial perception. It is the most common type of dementia among people older than 65, 
accounting for about 60%-70% of cases [1], associated with heterogeneous risks including 
genetic, epigenetic, dietary, and lifestyle factors [2].
The most striking and early symptom of AD is a loss of short-term memory (amnesia). 
When AD is suspected, the diagnosis is usually confirmed with behavioral assessments and 
cognitive tests, often followed by a brain scan. As the disorder progresses, cognitive 
impairment includes difficulty in producing or comprehending spoken or written language 
(aphasia), difficulty of execution of movements (apraxia), loss of perception (agnosia) [3], 
and disorientation [4]. AD may also involve behavioral changes, such as outbursts of 
violence or excessive passivity in people who have no previous history of such behavior [5, 
6]. Gradually, basic physiological functions are lost, ultimately leading to death.
AD afflicts at least 26 million people throughout the world [7] of which 5.4 million are 
Americans [8]. In the US, in 2011, it is estimated that at least $183 billion will be spent on 
direct AD care [8] and these costs will rise as the population ages. Several FDA-approved 
drugs are currently in use for the treatment of AD, however they mostly bring symptomatic 
relief and do not cure AD. Such an absence of treatment options sets the stage for the 
present review, which is primarily focused on the physiological role and utility of NMDAR 
antagonists, especially memantine, and its treatment not only for AD but other 
neurodegenerative disorders also, such as Vascular Dementia (VD) and Parkinson’s Disease 
(PD). The present review summarizes the recent advances in pathogenic processes 
underlying these diseases, including the amyloid pathway, pharmacology of NMDARs, 
glutamatergic transmission and the utility of NMDAR antagonists for therapy. Keeping the 
current interest of the field in mind, we will place a special emphasis on memantine 
treatment. It is worth mentioning that several aspects of memantine, such as its molecular 
basis [9], pharmacology [10] and clinical trials [11] have been previously discussed in this 
journal. However, the present review brings forward distinctly the unique role of memantine 
in treating AD, VD and PD in a comprehensive manner.
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ALZHEIMER’S DISEASE PATHOGENESIS, NMDARS AND MEMANTINE 
TREATMENT
Alzheimer’s Disease Pathology and NMDARs
Cognitive impairment in AD is caused, in large part, by the death of cholinergic neurons in 
the basal forebrain area [12]. Therefore, well characterized in the AD brain are a deficit in 
acetylcholine (ACh) and classical cholinergic markers, epitomized by choline 
acetyltransferase and acetylcholineseterase [2, 13].
AD neuropathology is routinely characterized by the accumulation of insoluble amyloid 
protein that originates from the amyloidogenic processing of a much larger metalloprotein – 
amyloid precursor protein (APP) [14] that leads to the formation of extracellular neuritic 
amyloid plaques containing the peptide- beta amyloid peptide (Aβ, see Fig. 1). The other 
major pathological hallmarks include neurofibrillary tangles (NFTs) that are comprised of 
misfolded, abnormally phosphorylated microtubule-associated tau protein [15], 
inflammatory changes with astrocytosis and microgliosis [16], oxidative stress [17, 18] and 
neuropil threads that have been found in the post-mortem AD brain [19], and in addition, a 
variety of other neurochemical and cellular alterations that result in anatomic as well as 
functional impairment of the neurotransmitter systems.
Although genetic, biochemical and neuropathological data strongly point to Aβ and amyloid 
plaque formation as a central event in AD pathogenesis [20], the etiopathology of AD 
remains unclear. A considerable weight of data suggests that it is polygenic and 
multifactorial [21] and that, likely, Aβ metabolism is sensitive to a range of influences and 
multiple mechanisms that can cause a shift towards the pathogenic pathways that lead to AD 
[22]. A small fraction of patients develop AD before the age of 65 known as early onset 
familial AD (FAD) that is believed to be caused by ~200 mutations in one of three genes: 
APP (on chromosome 21), and presenilin-1 and −2 (PS1, PS2) (31, 177 and 14 mutations, 
respectively) [http://www.molgen.ua.ac.be/ADMutations]. A commonality of these 
numerous mutations is that they, albeit via different routes, increase generation of Aβ and, in 
particular, the ratio of Aβ42: Aβ40 [23]. Major evidence indicates that soluble aggregates of 
Aβ and Aβ-derived diffusible ligands (ADDLs) target synapses and impair memory and also 
can induce cellular dysfunction. Recently, it has been suggested that APP proteolysis 
generates additional fragments that contribute to neuronal dysfunction [24].
Aβ40 (40 amino acid residues) is the main soluble Aβ species that is found in the 
cerebrospinal fluid at low nanomolar concentrations [25]. Aβ42 (42 residues) is a minor Aβ 
species that is more fibrillogenic than Aβ40 and heavily enriched in interstitial plaque 
amyloid [26]. It is generally agreed that Aβ peptide neurotoxicity is dependent on its 
conformational state [27]. The in vitro solubility of synthetic Aβ42, in neutral aqueous 
solutions is lower than Aβ40, consequent to the hydophobicity of the additional 
carboxylterminal amino acids. Also, it has been demonstrated that soluble Aβ40 can be 
destabilized through seeding with Aβ42 fibrils [28]. However, the presence or 
overproduction of Aβ42 alone appears to be insufficient to initiate Aβ amyloid deposition. 
Overexpression of APP and consequential Aβ overproduction in transgenic mice models 
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rarely results in mice bearing full-blown Alzheimer’s-like neuropathology [29]. Rather, it 
appears more likely that additional neurochemical factors are required for Aβ amyloidosis.
Some of the potential disease-modifying treatments for AD include NMDAR blockade, use 
of P-sheet breakers, antioxidant strategies, Aβ-peptide vaccination, secretase inhibitors, APP 
synthesis inhibitors, cholesterol-lowering drugs, metal chelators and anti-inflammatory 
agents. Strategies targeting the Aβ protein directly include anti-Aβ immunization, γ- and P-
secretase inhibitors, aggregation inhibitors and copper/zinc chelators. Interest in the use of 
metal chelator drugs stems from recent research suggesting that Aβ plaque formation relies 
upon the binding of metal ions [22]. Cholinergic drugs such as donepezil, rivastigmine and 
galantamine represent primary treatments for AD and are based on increasing available 
levels of ACh to surviving neurons. However, they have not been shown to prevent neuronal 
death [30] or disease progression [31]. Therefore, the evaluation of potential AD treatments 
that target other mechanisms is a major focus of current investigation and offers the greatest 
potential to enhance clinical management.
Considerable evidence supports the role of dysregulated glutamate in the pathophysiology of 
neurodegenerative disorders and excitotoxicity [32]. Therefore, glutamate NMDARs have 
emerged as key therapeutic targets for AD.
Glutamate is the main excitant neurotransmitter in the mammalian brain, implicated in the 
excitatory postsynaptic transmission through several ionotropic and metabotropic glutamate 
receptors. There are three classes of glutamategated channels and a group of G-protein 
coupled glutamate receptors (which cause mobilization of Ca2+ from internal stores) [33, 
34] named according to their activating synthetic agonist: the α-amino 3-hydroxy 5-methyl 
4-isoxazole-propionic acid (AMPA) activated receptors, kainate activated receptors, and the 
N-methyl D-aspartate (NMDA) receptors, have great importance in long-term adaptive 
processes [35]. Among these, the ion channels coupled to classical NMDARs are generally 
the most permeable to Ca2+ [36], that can in turn function as a second messenger in various 
signaling pathways.
NMDA glutamate receptors are abundant and ubiquitously distributed throughout the central 
nervous system (CNS), playing a critical role in synaptic plasticity and the cellular processes 
that underlie learning and memory [37]. Long-term potentiation (LTP) is a representation of 
neuronal synaptic plasticity that consists of a brief induction phase that elicits a long-lasting 
enhancement in signal transmission between two neurons. A stimulus into a presynaptic cell 
releases neurotransmitters, mostly glutamate, onto the postsynaptic cell membrane. There, 
glutamate binds to AMPA receptors in the postsynaptic membrane and triggers the influx of 
positively charged Na+ ions into the postsynaptic cell, causing a short-lived depolarization 
called excitatory postsynaptic potential. In synapses that exhibit NMDAR-dependent LTP, 
sufficient depolarization plus binding of glutamate can unblock NMDARs and relieve the 
Mg2+ blockade of the NMDAR [38] allowing Ca2+ to flow into the cell.
NMDARs are tetrameric complexes (see Fig. 2) composed by two NR1 subunits (eight 
splice isoforms, see Fig. 3) that form the channel itself, and two NR2A, NR2B, NR2C or 
NR2D subunits (derived from four independent genes) [39]. NR2 subunits modulate the 
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characteristics of the NR1 channel; therefore each combination shows different 
physiological and pharmacological properties [34]. For example, in vitro recombinant 
NMDARs composed by NR1 and NR2B subunits result in much more sensitivity to the non-
competitive antagonist ifenprodil than the NR1/NR2A combination [40]. Recently, NR3 
subunits have been found [41], although NR1/NR3A or NR1/NR3B complexes are not 
activated by glutamate but rather elicit an excitatory response through glycine activation that 
is independent of Ca2+ influx. Glycine is a mandatory co-factor with glutamate for NMDA 
channel opening [42] for binding sites onto NR1 and NR2 subunits, respectively, although a 
more potent inducer than glycine, an uncommon amino acid, D-serine, has been found [43].
NMDARs have been implicated as a mediator of neuronal injury associated with many 
neurological disorders including ischemia, epilepsy, brain trauma, dementia, and 
neurodegenerative disorders, such as PD [44]. Pathological elevations of glutamate levels 
and possibly other disturbances that alter resting membrane potential (e.g. impaired 
metabolism) can cause over-stimulation of the NMDAR that can lead to cellular dysfunction 
and death [45]. Under normal conditions of synaptic transmission, the NMDAR channel is 
blocked by Mg2+ sitting within the channel and only activated for brief periods of time. 
However, under pathological conditions, the normal block of the ion channel by Mg2+ is 
removed and abnormally enhances NMDAR activity [46]. Over-activation of the receptor 
causes an excessive amount of Ca2+ influx into a neuron to then trigger a variety of 
processes that can lead to necrosis or apoptosis [47]. The latter process includes Ca2+ 
overload of mitochondria and the activation of caspases and Ca2+-dependent activation of 
neuronal nitric oxide synthase (nNOS), leading to increased nitric oxide (NO) production 
[48]. Mitochondrial Ca2+ overload disables the membrane electrochemical gradient and, 
therefore, the ATP synthesis [49]. In addition, as consequence of electron chain failure, there 
is an excessive reactive oxygen species (ROS) production, such as the superoxide anion 
(O2−) that reacts with NO producing peroxynitrite (ONOO−) that can in turn oxidize lipids, 
proteins and DNA [50]. Interestingly, Ca2+-triggered neurotoxicity depends on the activation 
of a determinate pathway, since Ca2+ influx through L-type voltage-gated channels or non-
NMDA receptors was not toxic to cells, while a similar Ca2+ load via NMDRs was 
neurotoxic [51]. Increased activity of nNOS is also associated with excitotoxic cell death 
[52]. The nNOS is physically tethered to NMDAR through the postsynaptic density protein 
of 95 kDa (PSD-95) [53] and is activated by Ca2+ entry via calmodulin [41]. In fact, 
increased levels of NO have been detected in animal models of stroke and neurodegenerative 
diseases [54, 55]. It has been shown that in PSD-95 mutant mice, the production of NO 
induced by Ca2+ entry via NMDR is blocked without affecting nNOS expression, indicating 
the specificity of NMDAR in neurotoxicity [53].
Importantly, elevations in extracellular glutamate are not necessary to invoke an excitotoxic 
mechanism. Excitotoxicity can come into play even with normal levels of glutamate if 
NMDAR activity is increased, e.g. when neurons are injured and, thus, become depolarized 
[56]. Much evidence shows that the AD pathogenic cascade includes an excitotoxic 
component. Application of Aβ has been shown to promote endocytosis of NMDARs in 
cortical neurons [57]. However, the specific effects of Aβ on excitotoxicity are not yet fully 
understood, and the exact role of NMDAR activation in AD remains unclear, although 
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several studies have evidenced that Aβ could bind to NMDAR and increase Ca2+ influx into 
the cell [58].
Many potential neuroprotective agents block virtually all NMDAR activity and therefore, 
have unacceptable adverse effects, such as psychosis, nausea, vomiting, and a state called 
dissociative anesthesia, marked by catalepsy, amnesia, and analgesia. Neuronal cell death 
may accompany complete NMDAR blockade that may occur with high binding affinity of 
some drugs towards NMDARs [59]. Such possibilities dramatize the crucial role of the 
NMDAR in normal neuronal processes and explain why many NMDAR antagonists have 
disappointingly failed to advance in clinical trials for a number of neurodegenerative 
diseases. To be clinically acceptable, an anti-excitotoxic therapy must block excessive 
activation of the NMDAR while leaving normal function relatively intact to also avoid side 
effects. Drugs that simply compete with glutamate for the agonist binding site and block 
normal physiological functions do not meet this requirement. Both competitive glutamate 
and glycine antagonists, even although effective in preventing glutamate -mediated 
neurotoxicity, cause generalized inhibition of NMDAR activities [60]. Non-competitive 
antagonists, like MK-801, is an effective suppressor of excitotoxicity that acts allosterically 
(i.e. its binding site is other than the agonist’s) in the ion channel, but due to its high affinity, 
slow off-rate kinetics and a lesser voltage-dependent activity, blocks the channel for a 
clinically unacceptable period of time [60]. Such drugs have thus failed in clinical trials to 
date because of the development of adverse events occurring when the drugs are 
administered in their therapeutic range [59].
One mechanistic type of drug that can preferentially block higher, pathological levels of 
glutamate is an ‘uncompetitive’ antagonist that differs from non-competitive antagonists in 
that it requires receptor activation by an agonist before it can bind to a separate allosteric 
binding site. This uncompetitive mechanism of action, unlike competitive or non-
competitive antagonists, yields a drug that blocks NMDAR channels preferentially when it is 
excessively open and prevents an excessive flux of calcium inside the cell [61]. Most 
importantly, it does not substantially accumulate in the channel to interfere with normal 
synaptic transmission [60]. Evidence suggests that memantine acts by such a mechanism, 
given that it is a low, moderate affinity, uncompetitive NMDAR antagonist.
MEMANTINE TREATMENT FOR ALZHEIMER’S DISEASE
Memantine (1-amino-3,5-dimethyladamantane), an amino-alkyl cyclohexane derivative was 
first synthesized by Eli Lilly and Company (Indianapolis, IN) and patented in 1968, as 
documented in the Merck Index, as a derivative of adamantine, an anti-influenza agent. It 
possesses a three-ring (adamantane) structure with a bridgehead amine (−NH2) that, under 
physiological conditions, carries a positive charge that binds at or near the Mg2+ site within 
the NMDAR-associated channel.
Memantine was relatively ineffective at blocking the low levels of receptor activity 
associated with normal neurological function but becomes increasingly effective at higher 
concentrations of glutamate associated with over-activation of NMDARs [60]. During 
normal synaptic activity, NMDA channels are open on average for only several milliseconds, 
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and memantine is unable to act or accumulate within the channels; accordingly, synaptic 
activity continues largely unabated [56]. During prolonged activation of the receptor, 
however, as occurs under excitotoxic conditions, memantine becomes a highly effective 
blocker.
In addition to its low to moderate affinity, memantine blocks/unblocks the NMDAR ion 
channel with rapid kinetics and high voltage dependency [62]. These properties are thought 
to underlie the apparent ability of memantine to allow normal physiological function of the 
receptor while impairing pathological activation. Blocking NMDARs has also been reported 
to mitigate Aβ-induced degeneration of cholinergic neurons in the rat magnocellular nuclear 
basalis and in rat hippocampal neurons [63–65]. Preclinical data suggest that NMDAR-
mediated excitotoxicity may be linked to the effects of abnormal Aβ deposition in AD. More 
recently, memantine has been found to lower levels of secreted APP and Aβ peptide levels in 
neuronal cultures and in APP-Swe+PS1 AD transgenic mice [66, 67]. This is important as 
Aβ accumulation is the precipitating event in AD that leads to synaptic loss among other 
pathological features. Aβ is known to alter neuronal structure by mechanisms that involve 
the NMDARand inhibition of the NMDAR can reduce the toxic effects of Aβ.
As a currently approved drug, memantine is indicated for the symptomatic treatment of 
moderate to severe AD, and has been associated with a moderate decrease in clinical 
deterioration in AD [68]. Its usefulness has been proved in several clinical trials in which it 
has shown little but statistically significant improvements [69–72], also assessed by brain 
imaging [73]. Several systematic reviews of randomized controlled trials have established 
that memantine has small but helpful actions on cognition, mood, behavior, and the ability to 
perform daily activities in moderate to severe AD [74–76] nevertheless, the action of the 
drug in mild to moderate AD remains largely unknown. Importantly, memantine appears 
capable of achieving its pharmacological actions in a clinically well-tolerated manner and 
does not show the adverse effects typically associated with high-affinity NMDA-blockers. In 
trials reporting adverse effects, the primary memantine-induced adverse actions found were 
infrequent and comparable to placebo such as dizziness, occasional restlessness/agitation, 
constipation, ocular effects (cataracts, conjunctivitis), nausea, dyspnea, confusion, headache, 
fatigue, rash, diarrhea and urinary incontinence [77, 78]. On the basis of successful clinical 
trials, the use of memantine in the modulation of glutamatergic function may therefore 
represent a useful strategy for the treatment of AD. Furthermore, in vitro and clinical data 
indicate no adverse interactions between the approved cholinesterase inhibitors and 
memantine [79, 80].
Because memantine has exhibited efficacy and safety in placebo-controlled trials in patients 
with moderate to severe AD, the combination of memantine and various cholinesterase 
inhibitors appears well tolerated and they seem act synergistically due to their distinct 
mechanisms of action [81–85].
At present, a series of second generation memantine derivatives are currently in development 
and may have even greater neuroprotective properties than memantine [9, 86]. Whether and 
how these drugs translate to clinical medicine are awaited with interest.
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MEMANTINE TREATMENT FOR VASCULAR DEMENTIA
Memantine has also been described as effective and well tolerated for the treatment of mild 
to moderate VD in several randomized clinical trials [87–89]. VD ranks second in 
prevalence as a form of dementia after AD [1], and they often co-exist. It is not infrequent 
that confusion can occur between both disorders, due to the similarity of their clinical 
symptoms. VD is a degenerative cerebrovascular disease that leads to a progressive decline 
in memory and cognitive functioning. The root of this issue relates to a chronic reduced 
cerebral blood flow (vascular insufficiency) carrying oxygen and nutrients to the brain that 
may be impaired by a strategic infarct (ischemia) or small (silent) multi-infarcts, 
hemorrhagic cerebrovascular disease, or can derive from small vessel disease (including 
lacunar lesions and Binswanger’s disease) [90]. Apart from acute ischemia from embolic or 
atherothrombotic large vessels occlusion, ischemic-hypoxic brain lesions also can be 
originated by cardiovascular diseases, such as hypertension or diabetes, which cause a 
narrowing of the lumen of small vessels [91]. In addition, senile arteriolosclerosis produces 
tortuosity and elongation of arterioles [92].
Since it may be partly preventable, VD needs to be differentiated from other causes of 
dementia such as AD, Lewy body-type dementia and PD. Special attention has to be given 
when attempting to make a differential diagnosis, to the following steps that may lead to a 
diagnosis of VD [93]:
• Detection of vascular risk factors, including hypertension, diabetes, 
orthostatic hypotension, smoking, cardiac arrhythmias and heart failure.
• Examination of the cardiovascular system that may be a cause of 
thromboembolism that results in transient ischemic episodes and a history 
of strokes.
• Neurological and psychometric assessments to evidence particular 
neurological deficits.
• A search for treatable factors that might lead to VD, such as 
hypothyroidism, neurosyphilis, vitamin B12 deficiency, cerebral vasculitis 
or frontal lobe tumors.
Oxygen and glucose deprivation are followed by an elevation of extracellular glutamate both 
in ischemic brain damage and traumatic brain injury [50] that results in consequent NMDR 
overactivation and massive Ca2+ influx. Failure of astrocyte functions also has been reported 
[94] such as maintenance of blood-brain barrier (BBB) cells in cerebral microvasculature 
and endothelial permeability [95]. Disruption of tight junctions among endothelial cells, 
degradation of the basal lamina and extracellular matrix by metalloproteinases-2 and −9 are 
involved in BBB breakdown and cerebral hemorrhagia [96–98]. In addition, adhesion and 
transmigration of leukocyte occurs, leading to activation of an inflammatory response [99]. 
For a review of downstream processes after calcium entry in ischemia, see Ref. [48].
In general, cerebral lesions after ischemic injury begin with an initial reversible stage where 
neurons finally become necrotic [100]. The cells of the ischemic core undergo anoxic 
depolarizations that expand to the penumbral region and a lack of energy that leads to 
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necrosis [101]. Since the ischemic area grows as the number of peri-infarct depolarizations 
increases, the extension of severe damaged area can be attenuated by blocking NMDAR-
mediated depolarizations [102].
PARKINSON’S DISEASE PATHOGENESIS, NMDARS, GLUTAMATERGIC 
TRANSMISSION AND MEMANTINE TREATMENT
Parkinson’s Disease Pathology, NMDARs and Glutamatergic Transmission
PD is the second most frequent progressive-type neurodegenerative disorder after AD [103] 
and represents, like AD, a large health burden to society. Approximately 1% of the 
population over 60 years of age is affected [104]. Classical clinical symptoms include 
tremors; bradykinesia, or slowness of movement; and rigidity, or akinesia.
The primary underlying pathology of PD is the loss of dopaminergic neurons in the 
substantia nigra pars compacta (SNpc) that innervates the striatum. At post-mortem 
examination, the depletion frequently exceeds 90% [105] with consequent loss of neuronal 
systems responsible for motor functions. Besides, cell death is not limited to dopaminergic 
neurons in SNpc and can expand to other areas of the brain, leading to extensive neuronal 
death. It is not infrequent to find dementia in patients afflicted by PD. A further archetypal 
hallmark is the formation of intracytoplasmic inclusions, termed Lewy bodies, in remaining 
neurons [106].
To date, no curative treatment for PD exists but symptomic control can be achieved. The 
most effective treatments are based on the replacement of dopamine (DA) loss using either 
the precursor of DA, L-dihydroxyphenylalanine (L-dopa), or agonist-mediated stimulators of 
DA receptors, epitomized by pramipexole or ropinirole. Essentially, all patients require L-
dopa at some stage of disease progression, in spite of its adverse effects, such as the 
“wearing-off” phenomenon – relating to the shortening of sustainable pharmacological 
activity [107] as occurs when the symptoms of PD, attenuated by the treatment, become 
more intense prior to the next expected dose. Albeit that L-dopa is associated with 
dyskinesia or diminished voluntary movements and the presence of involuntary movements, 
it must be recognized that, since L-dopa’s clinical introduction, survival with PD has been 
considerably prolonged [108].
NMDARs are very abundant in the striatum [109], comprised by putamen and caudate 
nucleus, where they regulate the release of neurotransmitters like γ-aminobutyric acid 
(GABA) and ACh [110]. NMDARs downstream of the striatum also participate in 
modulating the activities of basal ganglia circuit and are present in the subthalamic nucleus 
(STN), globus pallidus internus (GPi) [111], and cerebral cortex [112]. The activity of 
NMDARs is largely regulated by dopaminergic afferents. D1 receptor agonists elicit a fast 
enhancement of NMDA-induced depolarization of striatal cells, whereas D2 receptor 
agonists attenuate this [113].
Execution of voluntary movement starts with the cortex (executive) signaling the caudate 
and putamen via glutamatergic projections or from the SNpc via dopamine. The Striatum 
then sends inhibitory GABAergic signals to GPi leads to disinhibition of the thalamic ventral 
Olivares et al. Page 9
Curr Alzheimer Res. Author manuscript; available in PMC 2016 August 28.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
anterior (VA). This leads to stimulatory signaling of the motor cortex by the thalamic VA 
and initiation of movement. As described, PD is characterized by depletion of dopaminergic 
neurons, leading to a disinhibition of striatal neurons that have inhibitory D2 dopaminergic 
receptors and project to the globus pallidus externus (GPe), and to a decrease of striatal 
neuron activity projecting to the GPi and the substantia nigra pars reticulata (SNpr) that have 
D1 excitatory dopaminergic receptors [114]. All these striatal efferent pathways are 
mediated by GABA and are inhibitory so that GPe projection to the STN (also inhibitory) is 
reduced. Therefore, the suppression of dopaminergic modulation disinhibits STN neurons, 
rendering them overactive [115]. The enhanced activity of excitatory glutamatergic STN 
projections to GPi and SNpr (besides lack of inhibitory input from the GPe stated above) 
further enhance the activity of their GABAergic neurons [116]. Spontaneous movement is 
reduced by inhibiting the activity of thalamic glutamatergic and excitatory VA projections 
VA to the motor frontal cortex (see Fig. 4A and B). Acetylcholinergic neurons in the 
brainstem and basal forebrain areas, are regulated by prefrontal cortex glutamatergic 
projections, and seem to be of special relevance in modulating motor, emotional and 
mnemonic functions [117], therefore a decrease of thalamocortical input entails a deficit of 
ACh, leading to a decline in voluntary movements. Likewise, the striatum and SNpc can 
receive glutamatergic excitatory input from the neocortex [118].
Accordingly, increased activity of STN neurons has been described in monkeys treated with 
1-methyl 4-phenyl 1, 2, 3, 6-tetrahydropyridine (MPTP), a neurotoxin that induces 
parkinsonism in animal models [119], and NMDAR antagonists have been reported to 
provide potent neuroprotective action [120]. NMDARs localized to the STN also play a role 
in sustaining pathological hyperactivity observed in a 6-hydroxydopamine rat model of 
parkinsonism, and the infusion of a NMDAR antagonist into the STN normalized the 
activity of the basal ganglia [121].
NMDARs are also found on dopaminergic neurons in the SNpc [122]. Increased 
glutamatergic input to dopaminergic neurons through NMDARs might accelerate the 
degenerative process [118]. It has been reported that NMDAR antagonists elevate striatal 
DA release in vivo [123–125] and, given this, would likely be beneficial in PD. In testing 
this conjecture, the initial class of selective antagonists’ studies in parkinsonism were the 
phenylethanolamines. One of them, ifenprodil, shows anti-parkinsonian activity in reserpine-
treated rats and MPTP-treated monkeys [126].
The effect of an anti-PD medication can be enhanced by NMDAR antagonists. In animal 
models of PD, NMDAR antagonists have shown a potentiation of the anti-parkinsonian 
effect of L-dopa and locomotion [109]. Some anticholinergic drugs are also non-competitive 
antagonists of the NMDAR and, at therapeutic concentrations, may interact with NMDARs 
and palliate PD [127]. Just as anticholinergics are able to work as NMDA antagonists, 
NMDA antagonists also can function as anticholinergic agents [128] and normalize the 
glutamatergic control of corticostriatal ACh release. In the striatum, NMDA stimulation 
enhances the release of ACh, and antagonists can effectively inhibit this release [110].
Since oxidative products of DA play a role in dopaminergic cell death [129], the use of 
NMDA antagonists could additionally allow for a decrease in L-dopa dosage and, thereby, 
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diminish any potential oxidative damage. Other NMDA antagonists, such as 
dextromethorphan, have been reported to suppress dyskinesia in PD patients, but adverse 
effects (primarily drowsiness) at higher doses would likely limit such a treatment strategy 
[130]. On the other hand, amantadine (1-amino adamantine) a non-selective NMDA 
antagonist used to treat PD, provides mild L-dopa-induced anti-dyskinetic benefit with a 
moderate degree of NMDA antagonist activity [131]. Furthermore, in a large retrospective 
study, amantadine was associated with an increased lifespan in patients with PD, suggesting 
that it may have neuroprotective properties [132].
Memantine Treatment for Parkinson’s Disease
Given that memantine carries out its therapeutic action by targeting the glutamatergic 
transmission, and the role of NMDARs in basal ganglia for the development of PD 
symptoms, memantine has also been tested in parkinsonian patients with a degree of 
moderate success.
Although memantine’s chemical structure is related to amantadine’s, and they act in a 
somewhat similar pharmacological fashion, memantine does not appear to share the anti-
dyskinetic activity of amantadine [133]. However, like DA agonists and other NMDA 
antagonists, memantine is able to reverse neuroleptic-induced catalepsy [134].
Using patch-clamp techniques, it has been reported that memantine blocks the NMDA ion 
channel [135], binds to the MK-801 binding site of the NMDAR [136], and decreases 
NMDA-induced membrane currents. The mechanism of action postulated is a normalization 
of the corticostriatal glutamatergic activity and/or the subthalamopallidal pathways that are 
overactive in PD (see Fig. 4C and D). Contrasting with amantadine, in which anti-dyskinetic 
activity could be rationalized by blocking subthalamic activity, the anti-parkinsonian and 
synergistic effect of memantine could be due to the inhibition of glutamatergic transmission 
in the striatum, whereby striatonigral neurons are GABAergic and inhibitory, causing a 
decreased inhibition of nigrostriatal dopaminergic neurons in SNpc and thereby an elevation 
in DA release [137].
To investigate the primary efficacy of memantine, a double-blind crossover exploratory trial 
was designed [133], in which 12 patients with idiopathic PD were randomized to memantine 
or placebo during two weeks in an escalated dosage from 10 mg/day to 30 mg/day at day 7, 
and after this time, a single dose of L-dopa was administrated to each arm. Five patients 
were taking concomitant PD medication (but not amantadine). As expected, a clear anti-
parkinsonian activity was observed in terms of counteracting bradykinesia and resting 
tremor. A synergistic enhancement of L-dopa and memantine seemed evident with motor 
function. Side effects, mainly drowsiness and nausea, occurred with a similar frequency in 
both groups.
To further assess the efficacy of memantine, a randomized controlled study was performed 
with patients suffering from dementia with Lewy bodies or PD dementia that resulted in an 
improvement in the majority of variables stated in the clinical global impression of change 
test for the memantine group compared to placebo [138, 139] and a better response assessed 
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in other useful rating scales [140], while the proportion of adverse events was similar to 
placebo and improved L-dopa-related dyskinesia and the “off” effect [141].
CONCLUDING REMARKS
Several studies show how memantine positively impacts cognition and, hence, they lend 
credence to the hypothesis that neurotoxicity of glutamatergic overstimulation is involved in 
dementia. The neuroprotective properties of memantine have also been demonstrated in 
several in vitro experimental settings, albeit further studies are needed to examine whether 
memantine treatment and cholinergic treatments could ultimately prove to be 
complementary or even synergistic. Memantine has also shown efficacy in PD, revealing 
itself as a potentially promising new therapeutic option. Importantly, as memantine 
treatment is generally well tolerated, combining it with other therapies is a valuable and 
feasible option both with AD and PD. However, although memantine was approved for 
treating mild to moderate AD, its results are modest; therefore, a second generation of 
adamantane-based drugs are being designed in the hope of improving its clinical efficacy. In 
conclusion, given the wealth of data on NMDAR activity in AD, VD, and PD, memantine 
and other drugs that emerge in the NMDAR antagonist class are likely to have an 
increasingly significant role to play in the future treatment of these diseases.
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LIST OF ABBREVATIONS
Ach Acetylcholine
AD Alzheimer’s disease
ADDLs Aβ-derived diffusible ligands
Amantadine 1-Amino adamantine
AMPA α-Amino 3-hydroxy 5-methyl 4-isoxazolepropionic acid
APP Amyloid precursor protein
Aβ Beta amyloid peptide
BBB Blood-brain barrier
CNS Central nervous system
DA Dopamine
FAD Familial Alzheimer’s disease
GABA γ-Aminobutyric acid
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GPe Globus pallidus externus
GPi Globus pallidus internus
L-dopa L-dihydroxyphenylalanine
LTP Long-term potentiation
Memantine 1-Amino-3,5-dimethyladamantane
MPTP 1-Methyl 4-phenyl 1, 2, 3, 6-tetrahydropyridine
NFTs Neurofibrillary tangles
NMDA N-Methyl D-Aspartate
NOS and NO Nitric oxide synthase and nitric oxide
PCP Phencyclidine
PD Parkinson’s disease
PS1 and PS2 Presenilin-1 and Presenilin-2 protein
SNpc Substantia nigra pars compacta
SNpr Substantia nigra pars reticulate
STN Subthalamic nucleus
VD Vascular dementia
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Fig. (1). 
Schematic illustration of APP protein and its Aβ product after cleavage by α-, β- and γ-
secretases. β- and γ-secretase cleaves on the N- and C-terminal ends of the Aβ region 
respectively. γ-Secretase cleavage yields a 39–43 amino acid product. Long and more 
fiblillogenic 42–43 amino acid Aβ species are implicated in AD pathogenesis and may seed 
the formation of Aβ40 fibrils. Mutations in the APP gene and in genes encoding proteins 
known as presenilins increase the production of long Aβ. Presenilins-1 and −2 is thought 
function as γ-secretases (for a review, see [142]).
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Fig. (2). 
Depiction of the tetrameric NMDAR at rest (right) and activated after depolarization and 
binding of agonists glycine and glutamate, suppressing the magnesium channel blockade 
(left), where antagonists MK-801 and memantine have their allosteric binding site.
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Fig. (3). 
Schematic structure of eight NR1 receptor isoforms (NR1A–H). Exons 5, 21 and 22 encode 
three splice cassettes named N1, C1 and C2. Carboxy-terminals variants are generated by 
splicing out of cassettes C1 and/or C2; and amino-terminal variant, by splicing out of N1. If 
C2 is excised, the first stop codon is suppressed, resulting in a new open reading frame that 
encodes the sequence named C2’ [143].
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Fig. (4). 
Classical model of normal activity of the basal ganglia and malfunctioning in PD (reviewed 
in Ref. [114]). Thin arrows indicate downregulation and thick arrows upregulation. Blue 
arrows show glutamatergic activatory efferents, red arrows indicate inhibitory GABAergic 
efferents and green arrows, activatory/inhibitory projections. (A) The ‘direct pathway’ is 
comprised of striatal neurons with D1 activatory dopaminergic receptors and their 
GABAergic efferent projections to the globus pallidus internus (GPi) which together the 
SNpr transmit inhibitory signals via GABAergic output to the thalamic ventral anterior (VA) 
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nucleus. The ‘indirect pathway’ is comprised of striatal neurons with D2 inhibitory 
dopaminergic receptors. The striatum (composed of caudate and putamen) projects 
GABAergic output to the globus pallidus externus (GPe). From this point, they synapse to 
the nucleus subthalamicus (STN), from which glutamatergic activatory projections reach the 
GPi and the substantia nigra (SNpc/SNpr). The subthalamic nucleus also gets excitatory 
input directly from the cortex and induces the GPi to increase GABA release in the VA. 
While GPe keeps it in check, the SNpc dopamine binds D2 receptors to inhibit this pathway, 
blocking the inhibition of the subthalamic circuit by GPe. Additionally, the striatum and the 
SNpc receive glutamatergic efferents from the neocortex.
(B) Loss of dopaminergic afferents (broken green arrows) entails a dis-repression of striatal 
D2 neurons leads to over-activity of their GABAergic projections to the GPe, and this in turn 
decreases its GABAergic efferent activity to the STN. As a consequence, STN glutamatergic 
projections to the GPi render over-active, increasing GABAergic output from the GPi to the 
VA. On the contrary, the D1 striatal neurons are underactive, therefore the GABAergic 
output to the GPi and to the SNpr are reduced and consequently the GABAergic output from 
both to the VA is increased. As a consequence in both cases, the loss of dopaminergic 
projections causes a failure to desinhibit the thalamocortical output, leading to bradykinesia, 
a typical symptom in PD. (C) (D) Possible targets at the basal ganglia level of NMDAR 
antagonists amantadine and memantine. Broken arrows mean suppression of output 
projections. A putative target is the STN (C), overactive in PD by blocking the subthalamic 
stimulation of GPi and a normalization of downstream thalamocortical connections. Other 
target could be the indirect pathway from the striatum (D), triggering a dis-repression of 
SNpr and leading to a normalization of STN activity and therefore a thalamic-cortical 
neuron well-functioning.
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